Entering text into the input field will update the search result below

AstraZeneca's Lynparza OK'd in Europe for BRCA+ pancreatic cancer

Jul. 08, 2020 6:50 AM ETAstraZeneca PLC (AZN)AZNBy: Douglas W. House, SA News Editor
  • The European Commission has approved AstraZeneca's (NYSE:AZN) PARP inhibitor Lynparza (olaparib) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer.
  • About 5-7% of metastatic pancreatic cancer patients have such a germline mutation.
  • Lynparza is approved in the U.S. and several other countries as first-line maintenance treatment for these patients.
  • Shares up a fraction premarket.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.